A previously healthy 30-year-old primiparous woman at 39 weeks’ gestation presented to her family physician with decreased fetal movement and was referred to triage at the labour and delivery unit. She had a 4-day history of right upper quadrant pain, cramping, nausea, vomiting and anorexia. She had no headache, visual changes, chest pain, dyspnea or edema to suggest preeclampsia. She was normotensive and tachycardic (heart rate 115 beats/min), and her cardiorespiratory examinations were unremarkable. Her abdomen was tender to palpation. Investigations revealed anemia with a hemoglobin level of 83 (normal range 120–160) g/L, thrombocytopenia, a normal creatinine level and an elevated protein-to-creatinine ratio (Table 1). Her hemoglobin level had been normal 8 weeks previously. Fetal heart rate abnormalities were seen with a sudden, severe and prolonged deceleration, and the patient was moved to the operating room for an emergency cesarian delivery.
View this table:
Table 1:
Laboratory results of a 39-year-old woman (39 wk gestation) from initial presentation to 7 days postpartum
In the operating room, the patient had a hemoperitoneum of about 700 mL with unclear origin. We consulted the general surgery team emergently for intraoperative exploration, but the source of the hemoperitoneum was not identified. The team delivered a live female infant with Apgar scores of 9 at 1 and 5 minutes. The patient’s estimated blood loss was 1795 mL and she was resuscitated with packed red blood cells, platelets, tranexamic acid and activated fibrinogen. She also received a total of 9 g of intravenous magnesium sulfate (bolus and subsequent infusion), given the concern for evolving preeclampsia. Postoperative computed tomography (CT) of her abdomen and pelvis using a multiphasic abdomen protocol (unenhanced, arterial and portal venous phase) showed a large subcapsular liver hematoma (5.8 × 16.4 × 19.3 cm) with rupture through the hepatic capsule and extension along the right paracolic gutter into the pelvis (Figure 1) and a partially occlusive left gonadal (ovarian) vein thrombosis with extension into the left proximal renal vein. Three sites of active extravasation were identified and confirmed with digital subtraction angiography to originate from branches of the right hepatic artery. These sites were embolized successfully with a slurry of hemostatic absorbable gelatin powder.
<a href=”https://www.cmaj.ca/content/cmaj/195/45/E1543/F1.large.jpg?width=800&height=600&carousel=1″ title=”Coronal portal venous phase computed tomography scan of a 39-year-old woman after emergent cesarean delivery at 39 weeks’ gestation, showing subcapsular liver hematoma breaking through the liver capsule (arrows) and extension along the right paracolic gutter.” class=”highwire-fragment fragment-images colorbox-load” rel=”gallery-fragment-images-1873405200″ data-figure-caption=”
Coronal portal venous phase computed tomography scan of a 39-year-old woman after emergent cesarean delivery at 39 weeks’ gestation, showing subcapsular liver hematoma breaking through the liver capsule (arrows) and extension along the right paracolic gutter.
” data-icon-position data-hide-link-title=”0″>
Figure 1:
Coronal portal venous phase computed tomography scan of a 39-year-old woman after emergent cesarean delivery at 39 weeks’ gestation, showing subcapsular liver hematoma breaking through the liver capsule (arrows) and extension along the right paracolic gutter.
Postoperatively, the patient reported gradually resolving abdominal pain and distension. On postpartum day 2, she developed hypertension (peak blood pressure 151/100 mm Hg) and we started her on oral nifedipine XL (30 mg every 12 h). Based on clinical and laboratory abnormalities, we diagnosed preeclampsia complicated by hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome (Table 1). We also diagnosed acute kidney injury after comparing her presenting creatinine level to her improved creatinine level postpartum in the absence of a pre-pregnancy baseline.
A CT scan on postpartum day 2 showed hypoattenuation consistent with hepatic infarction, likely as a complication of hepatic artery embolization, and stable appearance of both the hematoma and ovarian vein thrombosis (Figure 2). Her blood pressure was well controlled on oral nifedipine XL, and she was discharged on postpartum day 5 in stable condition.
<a href=”https://www.cmaj.ca/content/cmaj/195/45/E1543/F2.large.jpg?width=800&height=600&carousel=1″ title=”Coronal portal venous phase computed tomography scan of a 39-year-old woman on postpartum day 2 showing gonadal vein thrombus (arrows) and stable appearance of hepatic hematoma.” class=”highwire-fragment fragment-images colorbox-load” rel=”gallery-fragment-images-1873405200″ data-figure-caption=”
Coronal portal venous phase computed tomography scan of a 39-year-old woman on postpartum day 2 showing gonadal vein thrombus (arrows) and stable appearance of hepatic hematoma.
” data-icon-position data-hide-link-title=”0″>
Figure 2:
Coronal portal venous phase computed tomography scan of a 39-year-old woman on postpartum day 2 showing gonadal vein thrombus (arrows) and stable appearance of hepatic hematoma.
Three weeks postpartum, the patient was seen in the obstetric internal medicine clinic. Her blood pressure ranged from 110 to 120/60 to 80 mm Hg and nifedipine was stopped. Eight weeks postpartum, she remained normotensive.
Discussion
Hypertensive disorders of pregnancy, including severe manifestations such as preeclampsia, are increasingly common, with a reported doubling in prevalence between 2000 and 2018 in the United States.1 These disorders exist on a spectrum, including chronic or pre-existing hypertension, gestational hypertension and preeclampsia, with further characterization based on associated complications such as HELLP syndrome. According to the most recent guideline from the Society of Obstetricians and Gynecologists of Canada (SOGC), preeclampsia is diagnosed based on when hypertension is present with any one or more of new proteinuria; an adverse condition affecting the central nervous system, cardiorespiratory, hematologic, renal, hepatic or fetoplacental systems; or severe end-organ complications (SOGC Guideline No. 426 includes full diagnostic criteria).2 The syndrome of HELLP is an uncommon complication in pregnancy, affecting 1% of pregnancies but occurring in 10%–20% of patients who develop preeclampsia.3 It is typically associated with hypertension; however, 10%–20% of patients are normotensive. 4 Our patient met criteria for both preeclampsia (based on her elevated blood pressure and multiple adverse conditions and complications) and HELLP (based on evidence of hemolysis, elevated liver enzymes and low platelets), complicated by subcapsular liver hematoma. The initial biochemical abnormalities may have been explained by hemorrhage and prerenal acute kidney injury with intravascular depletion. However, the evolution of worsened anemia, thrombocytopenia, elevated liver enzymes and evidence of hemolysis, in parallel with development of hypertension, was most consistent with a unifying diagnosis of severe preeclampsia and HELLP syndrome, with associated complications of each including acute kidney injury, subcapsular liver hematoma and thrombosis.
Subcapsular liver hematoma is an uncommon complication of HELLP syndrome, reported in less than 2% of pregnancies with HELLP syndrome.5 It can progress to liver rupture or infarct, which can have devastating consequences for both the patient and baby if not promptly recognized and managed.5 Patients can present with dyspnea; shoulder, back or epigastric pain; anorexia; or nausea and vomiting, as was the case for our patient.5 Our patient was managed collaboratively by specialists in obstetrics and gynecology, general surgery, interventional radiology and obstetric internal medicine from an operative and medical perspective, given the atypical presentation, severe manifestations requiring emergent intervention and incidental finding of partially occlusive gonadal vein thrombosis.
The management options for subcapsular liver hematoma range from a conservative approach (i.e., hemodynamic support, transfusion and reversal of coagulopathy), to minimally invasive transcatheter hepatic artery embolization, to surgical intervention with packing, parenchymal suturing, resection or hepatic artery interruption.6 Some patients require liver transplantation.6 A recent systematic review reported maternal and fetal survival rates of 85% and 59% respectively, suggesting that these rates have remained largely unchanged over the last decade.7 However, this is an improvement when compared with data collected before 2003, which estimated a maternal survival rate of 61%.7 In a 2021 review of 73 patients with subcapsular liver hematoma, the best maternal and fetal survival rates were observed among those treated with hepatic artery embolization. 7 A minimally invasive approach with embolization should therefore be strongly considered as the first intervention if clinical stability allows, highlighting the importance of performing CT angiography in patients with HELLP syndrome with abdominal pain or elevated liver enzymes to facilitate timely diagnosis and management. 7 Computed tomography angiography provides both diagnostic information (particularly among patients who present with abdominal pain and abnormal liver enzymes, but who do not have indication for urgent cesarian delivery) and opportunity for minimally invasive therapy, and can be used to identify other pathology that may explain or be associated with the patient’s presentation. Open surgical intervention has been suggested as a rescue option for patients who are clinically unstable or when CT angiography is unavailable.7
Gonadal vein thrombosis is rare, with an incidence of 0.05%–0.16% in all pregnancies, most commonly in the postpartum period. Of these thromboses, 90% occur in the right gonadal vein because of its length and dextrorotation of the gravid uterus, resulting in compression. 8 Risk factors include infection and cesarian delivery, particularly with the birth of multiples.9 No consensus exists in the literature to guide treatment, and a recent review found no statistically significant correlation between use of anticoagulation and resolution of thrombosis.8 The authors of the review suggested treatment only in the presence of symptoms, such as septic thrombophlebitis and concurrent deep vein thrombosis or pulmonary embolism. Current SOGC recommendations presume an infectious trigger for gonadal vein thrombosis and support the use of broad-spectrum antibiotics, as well as consideration of therapeutic anticoagulation.9 The decision to treat with anticoagulation must be made on an individual basis, depending on the provoking factor, location and extent of thrombosis. For our patient, the left-sided location could suggest that the inflammatory and hypercoagulable states of preeclampsia and HELLP syndrome were more influential predisposing factors than anatomic changes associated with pregnancy. Based on the risk of recurrent bleeding in the setting of subcapsular liver hematoma and rupture, multifactorial anemia with evidence of hemolysis, the partially occlusive clot burden, the lack of extension into the inferior vena cava and the lack of evidence for an infectious trigger, we decided not to treat with anticoagulation or antibiotics.
We present a severe case of a patient with preeclampsia and HELLP — complicated by acute kidney injury, subcapsular hematoma and thrombosis — who initially presented with normal blood pressure, tachycardia and nausea and vomiting, and was found to have a hemoperitoneum intraoperatively. This case highlights the importance of having a high index of suspicion for preeclampsia or HELLP syndrome for patients with red-flag symptoms such as upper abdominal pain, headache, visual changes, altered mental status or dyspnea, and early biochemical signals, even in the absence of hypertension at presentation. Clinicians should consider prompt imaging and minimally invasive intervention if patient stability, resources and time permit.
Footnotes
Competing interests: None declared.
This article has been peer reviewed.
The authors have obtained patient consent.
Contributors: All of the authors contributed to the conception and design of the work, drafted the manuscript, revised it critically for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/
Some Ontario doctors have started offering a free shot that can protect babies from respiratory syncytial virus while Quebec will begin its immunization program next month.
The new shot called Nirsevimab gives babies antibodies that provide passive immunity to RSV, a major cause of serious lower respiratory tract infections for infants and seniors, which can cause bronchiolitis or pneumonia.
Ontario’s ministry of health says the shot is already available at some doctor’s offices in Ontario with the province’s remaining supply set to arrive by the end of the month.
Quebec will begin administering the shots on Nov. 4 to babies born in hospitals and delivery centers.
Parents in Quebec with babies under six months or those who are older but more vulnerable to infection can also book immunization appointments online.
The injection will be available in Nunavut and Yukon this fall and winter, though administration start dates have not yet been announced.
This report by The Canadian Press was first published Oct. 21, 2024.
-With files from Nicole Ireland
Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.
ISLAMABAD (AP) — Polio cases are rising ahead of a new vaccination campaign in Pakistan, where violence targeting health workers and the police protecting them has hampered years of efforts toward making the country polio-free.
Since January, health officials have confirmed 39 new polio cases in Pakistan, compared to only six last year, said Anwarul Haq of the National Emergency Operation Center for Polio Eradication.
The new nationwide drive starts Oct. 28 with the aim to vaccinate at least 32 million children. “The whole purpose of these campaigns is to achieve the target of making Pakistan a polio-free state,” he said.
Pakistan regularly launches campaigns against polio despite attacks on the workers and police assigned to the inoculation drives. Militants falsely claim the vaccination campaigns are a Western conspiracy to sterilize children.
Most of the new polio cases were reported in the southwestern Balochistan and southern Sindh province, following by Khyber Pakhtunkhwa province and eastern Punjab province.
The locations are worrying authorities since previous cases were from the restive northwest bordering Afghanistan, where the Taliban government in September suddenly stopped a door-to-door vaccination campaign.
Afghanistan and Pakistan are the two countries in which the spread of the potentially fatal, paralyzing disease has never been stopped. Authorities in Pakistan have said that the Taliban’s decision will have major repercussions beyond the Afghan border, as people from both sides frequently travel to each other’s country.
The World Health Organization has confirmed 18 polio cases in Afghanistan this year, all but two in the south of the country. That’s up from six cases in 2023. Afghanistan used a house-to-house vaccination strategy this June for the first time in five years, a tactic that helped to reach the majority of children targeted, according to WHO.
Health officials in Pakistan say they want the both sides to conduct anti-polio drives simultaneously.
WASHINGTON (AP) — Millions of people with private health insurance would be able to pick up over-the-counter methods like condoms, the “morning after” pill and birth control pills for free under a new rule the White House proposed on Monday.
Right now, health insurers must cover the cost of prescribed contraception, including prescription birth control or even condoms that doctors have issued a prescription for. But the new rule would expand that coverage, allowing millions of people on private health insurance to pick up free condoms, birth control pills, or “morning after” pills from local storefronts without a prescription.
The proposal comes days before Election Day, as Vice President Kamala Harris affixes her presidential campaign to a promise of expanding women’s health care access in the wake of the U.S. Supreme Court’s decision to undo nationwide abortion rights two years ago. Harris has sought to craft a distinct contrast from her Republican challenger, Donald Trump, who appointed some of the judges who issued that ruling.
“The proposed rule we announce today would expand access to birth control at no additional cost for millions of consumers,” Health and Human Services Secretary Xavier Becerra said in a statement. “Bottom line: women should have control over their personal health care decisions. And issuers and providers have an obligation to comply with the law.”
The emergency contraceptives that people on private insurance would be able to access without costs include levonorgestrel, a pill that needs to be taken immediately after sex to prevent pregnancy and is more commonly known by the brand name “Plan B.”
Without a doctor’s prescription, women may pay as much as $50 for a pack of the pills. And women who delay buying the medication in order to get a doctor’s prescription could jeopardize the pill’s effectiveness, since it is most likely to prevent a pregnancy within 72 hours after sex.
If implemented, the new rule would also require insurers to fully bear the cost of the once-a-day Opill, a new over-the-counter birth control pill that the U.S. Food and Drug Administration approved last year. A one-month supply of the pills costs $20.
Federal mandates for private health insurance to cover contraceptive care were first introduced with the Affordable Care Act, which required plans to pick up the cost of FDA-approved birth control that had been prescribed by a doctor as a preventative service.
The proposed rule would not impact those on Medicaid, the insurance program for the poorest Americans. States are largely left to design their own rules around Medicaid coverage for contraception, and few cover over-the-counter methods like Plan B or condoms.
